Cyclo Therapeutics Inc. (NASDAQ:CYTH) currently has a daily average trading volume of 38.33K but it saw 325663 shares traded on Wednesday. With a market cap of 10.74M USD, stock’s current market price of $1.24 came rising about 30.51 while comparing to the previous closing price of $0.95. In past 52 weeks, the stock remained buoying in the range of price level as high as $5.48 and as low as $0.91. In the recent trading on the day, stock has struck highest price mark of $1.30 while lowest mark touched by it was $0.93.
Taking a look at 20-day trading activity of Cyclo Therapeutics Inc. (CYTH) gives us an average price of $1.3665, while its current price level is -77.37% below from 52-week high level whereas it is 36.26% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.6921 while that of 200 days or SMA-200 reads an average of $2.3053. A closer look into the stock’s movement over the week reveals that its volatility is standing at 18.83% during that period while stretching the period over a month that decreases to 12.96%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 41.33 which implies that the stock is in neutral territory.
Cyclo Therapeutics Inc. (CYTH)’s stock is currently under the radar of 1 analysts who are in consensus at a 12-month price target range of between $5.00 and $5.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $5.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $5.00. Average price target assigned by them is $5.00 which highlights an upside potential of 75.2% for the stock over that period. And to attain the median price target of $5.00 assigned by those analysts, stock has to add about 75.2% of value to its current levels.
Data by FactSet Research shows that 1 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 1 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Moderate Buy.
Over the week, CYTH’s stock price is moving -2.36% down while it is -37.01% when we observe its performance for the past one month. Year-to-date it is -66.76% down and over the past year, the stock is showing a downside performance of -76.82%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$0.41 beat the consensus estimate of -$0.49 for the same. The company is expected to be releasing its next quarterly report in 03/13/2023, for which analysts forecasted an EPS of -$0.53 while estimate for next year EPS is -$1.83. For CYTH, analysts are forecasting an EPS-growth rate of 18.30% for current year and estimate for EPS growth in next year is 6.00%. In next quarter, company is expected to be making quarterly sales of $640k as analysts are expecting the sales for current fiscal year at $2.38 million and seeing the company making $2.85 million in sales next year. Moreover, analysts are in estimates of $620k for current-quarter revenue.
Currently, Cyclo Therapeutics Inc.’s total number of outstanding shares is 8.42M with 9.48% of that held by the insiders while 4.89% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -90.40% and return on equity (ROE) at -111.80%. Stock’s beta reads -0.51. Stock has a price to book (P/B) ratio of 1.07 while price to sale or P/S ratio amounts to 6.32. Its return on asset (ROA) is -88.20% on average.